<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36813473</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2053-8790</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Lupus science &amp; medicine</Title><ISOAbbreviation>Lupus Sci Med</ISOAbbreviation></Journal><ArticleTitle>Gut microbiota in SLE: from animal models to clinical evidence and pharmacological perspectives.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e000776</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/lupus-2022-000776</ELocationID><Abstract><AbstractText>Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease driven by complex interactions between genetics and environmental factors. SLE is characterised by breaking self-immune tolerance and autoantibody production that triggers inflammation and damage of multiple organs. Given the highly heterogeneous nature of SLE, the treatments currently used are still not satisfactory with considerable side effects, and the development of new therapies is a major health issue for better patient management. In this context, mouse models significantly contribute to our knowledge of the pathogenesis of SLE and are an invaluable tool for testing novel therapeutic targets. Here, we discuss the role of the most used SLE mouse models and their contribution to therapeutic improvement. Considering the complexity of developing targeted therapies for SLE, adjuvant therapies are also increasingly proposed. Indeed, murine and human studies have recently revealed that gut microbiota is a potential target and holds great promises for successful new SLE therapies. However, the mechanisms of gut microbiota dysbiosis in SLE remain unclear to date. In this review, we propose an inventory of existing studies investigating the relationship between gut microbiota dysbiosis and SLE to establish microbiome signature that may serve as a potential biomarker of the disease and its severity as well as a new potential therapy target. This approach may open new possibilities for early diagnosis, prevention and therapeutic perspectives of SLE based on gut microbiome.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Toumi</LastName><ForeName>Eya</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-6386-4074</Identifier><AffiliationInfo><Affiliation>Aix-Marseille Univ, MEPHI, IRD, APHM, Marseille, France toumieya37@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IHU M&#xe9;diterran&#xe9;e Infection, Aix-Marseille Universit&#xe9;, Marseille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>R&amp;D Department, Laboratoire Alphabio, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mezouar</LastName><ForeName>Soraya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Aix-Marseille Univ, MEPHI, IRD, APHM, Marseille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IHU M&#xe9;diterran&#xe9;e Infection, Aix-Marseille Universit&#xe9;, Marseille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Aix Marseille Univ, EFS, CNRS, ADES, 'Biologie des Groupes Sanguins', Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plauzolles</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>R&amp;D Department, Laboratoire Alphabio, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiche</LastName><ForeName>Laurent</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Infectious and Internal Medicine Department, H&#xf4;pital Europ&#xe9;en Marseille, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bardin</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Immunology Department, Hopital de la Conception, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Halfon</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Aix-Marseille Univ, MEPHI, IRD, APHM, Marseille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IHU M&#xe9;diterran&#xe9;e Infection, Aix-Marseille Universit&#xe9;, Marseille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>R&amp;D Department, Laboratoire Alphabio, Marseille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious and Internal Medicine Department, H&#xf4;pital Europ&#xe9;en Marseille, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Mege</LastName><ForeName>Jean Louis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Aix-Marseille Univ, MEPHI, IRD, APHM, Marseille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IHU M&#xe9;diterran&#xe9;e Infection, Aix-Marseille Universit&#xe9;, Marseille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Immunology Department, Hopital de la Conception, Marseille, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus Sci Med</MedlineTA><NlmUniqueID>101633705</NlmUniqueID><ISSNLinking>2053-8790</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="Y">Gastrointestinal Microbiome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064806" MajorTopicYN="N">Dysbiosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">autoimmunity</Keyword><Keyword MajorTopicYN="N">dysbiosis</Keyword><Keyword MajorTopicYN="N">gut microbiota</Keyword><Keyword MajorTopicYN="N">health services research</Keyword><Keyword MajorTopicYN="N">murine mouse models</Keyword><Keyword MajorTopicYN="N">patient care team</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">therapeutic strategy</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>22</Day><Hour>21</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36813473</ArticleId><ArticleId IdType="pmc">PMC9950977</ArticleId><ArticleId IdType="doi">10.1136/lupus-2022-000776</ArticleId><ArticleId IdType="pii">10/1/e000776</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tsokos GC. Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol 2020;21:605&#x2013;14. 10.1038/s41590-020-0677-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0677-6</ArticleId><ArticleId IdType="pmc">PMC8135909</ArticleId><ArticleId IdType="pubmed">32367037</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol 2016;12:605&#x2013;20. 10.1038/nrrheum.2016.137</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2016.137</ArticleId><ArticleId IdType="pubmed">27558659</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011;365:2110&#x2013;21. 10.1056/NEJMra1100359</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1100359</ArticleId><ArticleId IdType="pubmed">22129255</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Davidson A. Taming lupus-a new understanding of pathogenesis is leading to clinical advances. Nat Med 2012;18:871&#x2013;82. 10.1038/nm.2752</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2752</ArticleId><ArticleId IdType="pmc">PMC3607103</ArticleId><ArticleId IdType="pubmed">22674006</ArticleId></ArticleIdList></Reference><Reference><Citation>Musa R, Brent LH, Qurie A. Lupus nephritis. StatPearls, 2022.</Citation></Reference><Reference><Citation>Hruskova Z, Tesar V. Lessons learned from the failure of several recent trials with biologic treatment in systemic lupus erythematosus. Expert Opin Biol Ther 2018;18:989&#x2013;96. 10.1080/14712598.2018.1504918</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14712598.2018.1504918</ArticleId><ArticleId IdType="pubmed">30040494</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou MG, Wang Z, Dasgupta A, et al. . Burden of serious infections in adults with systemic lupus erythematosus: a national population-based study, 1996-2011. Arthritis Care Res (Hoboken) 2015;67:1078&#x2013;85. 10.1002/acr.22575</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.22575</ArticleId><ArticleId IdType="pmc">PMC4516647</ArticleId><ArticleId IdType="pubmed">25732901</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry D, Sang A, Yin Y, et al. . Murine models of systemic lupus erythematosus. J Biomed Biotechnol 2011;2011:271694. 10.1155/2011/271694</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2011/271694</ArticleId><ArticleId IdType="pmc">PMC3042628</ArticleId><ArticleId IdType="pubmed">21403825</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Titov AA, Morel L. An update on lupus animal models. Curr Opin Rheumatol 2017;29:434&#x2013;41. 10.1097/BOR.0000000000000412</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000412</ArticleId><ArticleId IdType="pmc">PMC5815391</ArticleId><ArticleId IdType="pubmed">28537986</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard ML, Gilkeson G. Mouse models of lupus: what they tell us and what they do &#x2019;'t. Lupus Sci Med 2018;5:e000199. 10.1136/lupus-2016-000199</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2016-000199</ArticleId><ArticleId IdType="pmc">PMC5786947</ArticleId><ArticleId IdType="pubmed">29387435</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuman H, Koren O. The gut microbiota: a possible factor influencing systemic lupus erythematosus. Curr Opin Rheumatol 2017;29:374&#x2013;7. 10.1097/BOR.0000000000000395</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000395</ArticleId><ArticleId IdType="pubmed">28376066</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz-Agranov N, Zandman-Goddard G. The microbiome links between aging and lupus. Autoimmun Rev 2021;20:102765. 10.1016/j.autrev.2021.102765</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102765</ArticleId><ArticleId IdType="pubmed">33476814</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu Q, Zhang H, Liao X, et al. . Control of lupus nephritis by changes of gut microbiota. Microbiome 2017;5:73. 10.1186/s40168-017-0300-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40168-017-0300-8</ArticleId><ArticleId IdType="pmc">PMC5505136</ArticleId><ArticleId IdType="pubmed">28697806</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y, Xu X, Li M, et al. . Gut microbiota promote the inflammatory response in the pathogenesis of systemic lupus erythematosus. Mol Med 2019;25:35. 10.1186/s10020-019-0102-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10020-019-0102-5</ArticleId><ArticleId IdType="pmc">PMC6676588</ArticleId><ArticleId IdType="pubmed">31370803</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews BS, Eisenberg RA, Theofilopoulos AN, et al. . Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med 1978;148:1198&#x2013;215. 10.1084/jem.148.5.1198</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.148.5.1198</ArticleId><ArticleId IdType="pmc">PMC2185049</ArticleId><ArticleId IdType="pubmed">309911</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon FJ, Andrews BS, Eisenberg RA, et al. . Etiology and pathogenesis of a spontaneous lupus-like syndrome in mice. Arthritis Rheum 1978;21:S64&#x2013;7. 10.1002/art.1780210909</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780210909</ArticleId><ArticleId IdType="pubmed">307393</ArticleId></ArticleIdList></Reference><Reference><Citation>Boneparth A, Woods M, Huang W, et al. . The effect of BAFF inhibition on autoreactive B-cell selection in murine systemic lupus erythematosus. Mol Med 2016;22:173&#x2013;82. 10.2119/molmed.2016.00022</Citation><ArticleIdList><ArticleId IdType="doi">10.2119/molmed.2016.00022</ArticleId><ArticleId IdType="pmc">PMC5004722</ArticleId><ArticleId IdType="pubmed">26882090</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramanujam M, Bethunaickan R, Huang W, et al. . Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice. Arthritis Rheum 2010;62:1457&#x2013;68. 10.1002/art.27368</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27368</ArticleId><ArticleId IdType="pmc">PMC2917190</ArticleId><ArticleId IdType="pubmed">20131293</ArticleId></ArticleIdList></Reference><Reference><Citation>Izui S, Kelley VE, Masuda K, et al. . Induction of various autoantibodies by mutant gene lpr in several strains of mice. J Immunol 1984;133:227&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">6609979</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg YJ, Steinberg AD, Santoro TJ. The basis of autoimmunity in MRL-lpr/lpr mice: a role for self ia-reactive T cells. Immunol Today 1984;5:64&#x2013;7. 10.1016/0167-5699(84)90166-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0167-5699(84)90166-X</ArticleId><ArticleId IdType="pubmed">25291514</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen PL, Eisenberg RA. The lpr and gld genes in systemic autoimmunity: life and death in the Fas Lane. Immunol Today 1992;13:427&#x2013;8. 10.1016/0167-5699(92)90066-G</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0167-5699(92)90066-G</ArticleId><ArticleId IdType="pubmed">1282318</ArticleId></ArticleIdList></Reference><Reference><Citation>Adachi M, Watanabe-Fukunaga R, Nagata S. Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice. Proc Natl Acad Sci U S A 1993;90:1756&#x2013;60. 10.1073/pnas.90.5.1756</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.90.5.1756</ArticleId><ArticleId IdType="pmc">PMC45958</ArticleId><ArticleId IdType="pubmed">7680478</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen SR, Shupe J, Nickerson K, et al. . Toll-Like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006;25:417&#x2013;28. 10.1016/j.immuni.2006.07.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2006.07.013</ArticleId><ArticleId IdType="pubmed">16973389</ArticleId></ArticleIdList></Reference><Reference><Citation>Reilly CM, Mishra N, Miller JM, et al. . Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. J Immunol 2004;173:4171&#x2013;8. 10.4049/jimmunol.173.6.4171</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.173.6.4171</ArticleId><ArticleId IdType="pubmed">15356168</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Z, Tan W, Ji J, et al. . Rapamycin reverses the senescent phenotype and improves immunoregulation of mesenchymal stem cells from MRL/lpr mice and systemic lupus erythematosus patients through inhibition of the mTOR signaling pathway. Aging (Albany NY) 2016;8:1102&#x2013;14. 10.18632/aging.100925</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.100925</ArticleId><ArticleId IdType="pmc">PMC4931856</ArticleId><ArticleId IdType="pubmed">27048648</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra N, Reilly CM, Brown DR, et al. . Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest 2003;111:539&#x2013;52. 10.1172/JCI16153</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI16153</ArticleId><ArticleId IdType="pmc">PMC151922</ArticleId><ArticleId IdType="pubmed">12588892</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Alba JC, Gir&#xf3;n-P&#xe9;rez DA, Romero-Ram&#xed;rez H, et al. . Regulatory IFN-&#x3b3;-producing killer dendritic cells are enhanced in B6.MLR-faslpr /J lupus-prone mice. Eur J Immunol 2018;48:1851&#x2013;60. 10.1002/eji.201847547</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201847547</ArticleId><ArticleId IdType="pubmed">30289564</ArticleId></ArticleIdList></Reference><Reference><Citation>Merino R, Fossati L, Izui S. The lupus-prone bxsb strain: the yaa gene model of systemic lupus erythematosus. Springer Semin Immunopathol 1992;14:141&#x2013;57. 10.1007/BF00195291</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00195291</ArticleId><ArticleId IdType="pubmed">1475741</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane JA, Pisitkun P, Barrett RS, et al. . Control of Toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity 2007;27:801&#x2013;10. 10.1016/j.immuni.2007.09.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2007.09.009</ArticleId><ArticleId IdType="pmc">PMC2706502</ArticleId><ArticleId IdType="pubmed">17997333</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008;358:929&#x2013;39. 10.1056/NEJMra071297</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra071297</ArticleId><ArticleId IdType="pubmed">18305268</ArticleId></ArticleIdList></Reference><Reference><Citation>Freitas EC, de Oliveira MS, Monticielo OA. Pristane-induced lupus: considerations on this experimental model. Clin Rheumatol 2017;36:2403&#x2013;14. 10.1007/s10067-017-3811-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-017-3811-6</ArticleId><ArticleId IdType="pubmed">28879482</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh M, Reeves WH. Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane. J Exp Med 1994;180:2341&#x2013;6. 10.1084/jem.180.6.2341</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.180.6.2341</ArticleId><ArticleId IdType="pmc">PMC2191761</ArticleId><ArticleId IdType="pubmed">7964507</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh M, Kumar A, Kanwar YS, et al. . Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane. Proc Natl Acad Sci U S A 1995;92:10934&#x2013;8. 10.1073/pnas.92.24.10934</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.92.24.10934</ArticleId><ArticleId IdType="pmc">PMC40545</ArticleId><ArticleId IdType="pubmed">7479913</ArticleId></ArticleIdList></Reference><Reference><Citation>Reeves WH, Lee PY, Weinstein JS, et al. . Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol 2009;30:455&#x2013;64. 10.1016/j.it.2009.06.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2009.06.003</ArticleId><ArticleId IdType="pmc">PMC2746238</ArticleId><ArticleId IdType="pubmed">19699150</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee PY, Weinstein JS, Nacionales DC, et al. . A novel type I IFN-producing cell subset in murine lupus. J Immunol 2008;180:5101&#x2013;8. 10.4049/jimmunol.180.7.5101</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.180.7.5101</ArticleId><ArticleId IdType="pmc">PMC2909121</ArticleId><ArticleId IdType="pubmed">18354236</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokogawa M, Takaishi M, Nakajima K, et al. . Epicutaneous application of toll-like receptor 7 agonists leads to systemic autoimmunity in wild-type mice: A new model of systemic lupus erythematosus. Arthritis Rheumatol 2014;66:694&#x2013;706. 10.1002/art.38298</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38298</ArticleId><ArticleId IdType="pubmed">24574230</ArticleId></ArticleIdList></Reference><Reference><Citation>Kostic AD, Howitt MR, Garrett WS. Exploring host-microbiota interactions in animal models and humans. Genes Dev 2013;27:701&#x2013;18. 10.1101/gad.212522.112</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.212522.112</ArticleId><ArticleId IdType="pmc">PMC3639412</ArticleId><ArticleId IdType="pubmed">23592793</ArticleId></ArticleIdList></Reference><Reference><Citation>Spor A, Koren O, Ley R. Unravelling the effects of the environment and host genotype on the gut microbiome. Nat Rev Microbiol 2011;9:279&#x2013;90. 10.1038/nrmicro2540</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro2540</ArticleId><ArticleId IdType="pubmed">21407244</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton KJ, Satoh M, Swartz J, et al. . Influence of microbial stimulation on Hypergammaglobulinemia and autoantibody production in pristane-induced lupus. Clin Immunol Immunopathol 1998;86:271&#x2013;9. 10.1006/clin.1997.4481</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/clin.1997.4481</ArticleId><ArticleId IdType="pubmed">9557160</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Liao X, Sparks JB, et al. . Dynamics of gut microbiota in autoimmune lupus. Appl Environ Microbiol 2014;80:7551&#x2013;60. 10.1128/AEM.02676-14</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.02676-14</ArticleId><ArticleId IdType="pmc">PMC4249226</ArticleId><ArticleId IdType="pubmed">25261516</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BM, Gaudreau M-C, Gudi R, et al. . Gut microbiota differently contributes to intestinal immune phenotype and systemic autoimmune progression in female and male lupus-prone mice. J Autoimmun 2020;108:102420. 10.1016/j.jaut.2020.102420</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2020.102420</ArticleId><ArticleId IdType="pmc">PMC7204266</ArticleId><ArticleId IdType="pubmed">32019684</ArticleId></ArticleIdList></Reference><Reference><Citation>Weckerle CE, Niewold TB. The unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies. Clin Rev Allergy Immunol 2011;40:42&#x2013;9. 10.1007/s12016-009-8192-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-009-8192-4</ArticleId><ArticleId IdType="pmc">PMC2891868</ArticleId><ArticleId IdType="pubmed">20063186</ArticleId></ArticleIdList></Reference><Reference><Citation>Klaenhammer TR, Kleerebezem M, Kopp MV, et al. . The impact of probiotics and prebiotics on the immune system. Nat Rev Immunol 2012;12:728&#x2013;34. 10.1038/nri3312</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3312</ArticleId><ArticleId IdType="pubmed">23007572</ArticleId></ArticleIdList></Reference><Reference><Citation>Manirarora JN, Kosiewicz MM, Alard P. Feeding lactobacilli impacts lupus progression in (nzbxnzw) F1 lupus-prone mice by enhancing immunoregulation. Autoimmunity 2020;53:323&#x2013;32. 10.1080/08916934.2020.1777282</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08916934.2020.1777282</ArticleId><ArticleId IdType="pubmed">32552071</ArticleId></ArticleIdList></Reference><Reference><Citation>Toral M, Robles-Vera I, Romero M, et al. . Lactobacillus fermentum CECT5716: a novel alternative for the prevention of vascular disorders in a mouse model of systemic lupus erythematosus. FASEB J 2019;33:10005&#x2013;18. 10.1096/fj.201900545RR</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201900545RR</ArticleId><ArticleId IdType="pubmed">31173526</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo XM, Edwards MR, Mu Q, et al. . Gut microbiota in human systemic lupus erythematosus and a mouse model of lupus. Appl Environ Microbiol 2018;84:e02288&#x2013;17. 10.1128/AEM.02288-17</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.02288-17</ArticleId><ArticleId IdType="pmc">PMC5795066</ArticleId><ArticleId IdType="pubmed">29196292</ArticleId></ArticleIdList></Reference><Reference><Citation>Zegarra-Ruiz DF, El Beidaq A, I&#xf1;iguez AJ, et al. . A diet-sensitive commensal lactobacillus strain mediates TLR7-dependent systemic autoimmunity. Cell Host Microbe 2019;25:113&#x2013;27. 10.1016/j.chom.2018.11.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2018.11.009</ArticleId><ArticleId IdType="pmc">PMC6377154</ArticleId><ArticleId IdType="pubmed">30581114</ArticleId></ArticleIdList></Reference><Reference><Citation>Hufeldt MR, Nielsen DS, Vogensen FK, et al. . Variation in the gut microbiota of laboratory mice is related to both genetic and environmental factors. Comp Med 2010;60:336&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2958200</ArticleId><ArticleId IdType="pubmed">21262117</ArticleId></ArticleIdList></Reference><Reference><Citation>Safari Z, Bruneau A, Monnoye M, et al. . Murine genetic background overcomes gut microbiota changes to explain metabolic response to high-fat diet. Nutrients 2020;12:287. 10.3390/nu12020287</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12020287</ArticleId><ArticleId IdType="pmc">PMC7071469</ArticleId><ArticleId IdType="pubmed">31973214</ArticleId></ArticleIdList></Reference><Reference><Citation>Nam Y-D, Jung M-J, Roh SW, et al. . Comparative analysis of korean human gut microbiota by barcoded pyrosequencing. PLoS One 2011;6:e22109. 10.1371/journal.pone.0022109</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0022109</ArticleId><ArticleId IdType="pmc">PMC3146482</ArticleId><ArticleId IdType="pubmed">21829445</ArticleId></ArticleIdList></Reference><Reference><Citation>David LA, Maurice CF, Carmody RN, et al. . Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014;505:559&#x2013;63. 10.1038/nature12820</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12820</ArticleId><ArticleId IdType="pmc">PMC3957428</ArticleId><ArticleId IdType="pubmed">24336217</ArticleId></ArticleIdList></Reference><Reference><Citation>Arumugam M, Raes J, Pelletier E, et al. . Enterotypes of the human gut microbiome. Nature 2011;473:174&#x2013;80. 10.1038/nature09944</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09944</ArticleId><ArticleId IdType="pmc">PMC3728647</ArticleId><ArticleId IdType="pubmed">21508958</ArticleId></ArticleIdList></Reference><Reference><Citation>Hevia A, Milani C, L&#xf3;pez P, et al. . Intestinal dysbiosis associated with systemic lupus erythematosus. MBio 2014;5:e01548&#x2013;14. 10.1128/mBio.01548-14</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.01548-14</ArticleId><ArticleId IdType="pmc">PMC4196225</ArticleId><ArticleId IdType="pubmed">25271284</ArticleId></ArticleIdList></Reference><Reference><Citation>He Z, Shao T, Li H, et al. . Alterations of the gut microbiome in chinese patients with systemic lupus erythematosus. Gut Pathog 2016;8:64. 10.1186/s13099-016-0146-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13099-016-0146-9</ArticleId><ArticleId IdType="pmc">PMC5146896</ArticleId><ArticleId IdType="pubmed">27980687</ArticleId></ArticleIdList></Reference><Reference><Citation>Greiling TM, Dehner C, Chen X, et al. . Commensal orthologs of the human autoantigen Ro60 as triggers of autoimmunity in lupus. Sci Transl Med 2018;10:eaan2306. 10.1126/scitranslmed.aan2306</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aan2306</ArticleId><ArticleId IdType="pmc">PMC5918293</ArticleId><ArticleId IdType="pubmed">29593104</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Meulen TA, Harmsen HJM, Vila AV, et al. . Shared gut, but distinct oral microbiota composition in primary sj&#xf6;gren&#x2019;s syndrome and systemic lupus erythematosus. J Autoimmun 2019;97:77&#x2013;87. 10.1016/j.jaut.2018.10.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2018.10.009</ArticleId><ArticleId IdType="pubmed">30416033</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo M, Wang H, Xu S, et al. . Alteration in gut microbiota is associated with dysregulation of cytokines and glucocorticoid therapy in systemic lupus erythematosus. Gut Microbes 2020;11:1758&#x2013;73. 10.1080/19490976.2020.1768644</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2020.1768644</ArticleId><ArticleId IdType="pmc">PMC7524333</ArticleId><ArticleId IdType="pubmed">32507008</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei F, Xu H, Yan C, et al. . Changes of intestinal flora in patients with systemic lupus erythematosus in northeast china. PloS One 2019;14:e0213063. 10.1371/journal.pone.0213063</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0213063</ArticleId><ArticleId IdType="pmc">PMC6417672</ArticleId><ArticleId IdType="pubmed">30870437</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez P, de Paz B, Rodr&#xed;guez-Carrio J, et al. . Th17 responses and natural igm antibodies are related to gut microbiota composition in systemic lupus erythematosus patients. Sci Rep 2016;6:24072. 10.1038/srep24072</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep24072</ArticleId><ArticleId IdType="pmc">PMC4820712</ArticleId><ArticleId IdType="pubmed">27044888</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Wang H-F, Li X, et al. . Disordered intestinal microbes are associated with the activity of systemic lupus erythematosus. Clin Sci (Lond) 2019;133:821&#x2013;38. 10.1042/CS20180841</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CS20180841</ArticleId><ArticleId IdType="pubmed">30872359</ArticleId></ArticleIdList></Reference><Reference><Citation>den Besten G, van Eunen K, Groen AK, et al. . The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res 2013;54:2325&#x2013;40. 10.1194/jlr.R036012</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.R036012</ArticleId><ArticleId IdType="pmc">PMC3735932</ArticleId><ArticleId IdType="pubmed">23821742</ArticleId></ArticleIdList></Reference><Reference><Citation>Keku TO, Dulal S, Deveaux A, et al. . The gastrointestinal microbiota and colorectal cancer. Am J Physiol Gastrointest Liver Physiol 2015;308:G351&#x2013;63. 10.1152/ajpgi.00360.2012</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00360.2012</ArticleId><ArticleId IdType="pmc">PMC4346754</ArticleId><ArticleId IdType="pubmed">25540232</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng L, Li Z-R, Green RS, et al. . Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr 2009;139:1619&#x2013;25. 10.3945/jn.109.104638</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/jn.109.104638</ArticleId><ArticleId IdType="pmc">PMC2728689</ArticleId><ArticleId IdType="pubmed">19625695</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzouz D, Omarbekova A, Heguy A, et al. . Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal. Ann Rheum Dis 2019;78:947&#x2013;56. 10.1136/annrheumdis-2018-214856</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214856</ArticleId><ArticleId IdType="pmc">PMC6585303</ArticleId><ArticleId IdType="pubmed">30782585</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B, Jia X-M, Xu J-Y, et al. . An autoimmunogenic and proinflammatory profile defined by the gut microbiota of patients with untreated systemic lupus erythematosus. Arthritis Rheumatol 2021;73:232&#x2013;43. 10.1002/art.41511</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41511</ArticleId><ArticleId IdType="pubmed">33124780</ArticleId></ArticleIdList></Reference><Reference><Citation>Assimakopoulos SF, Triantos C, Thomopoulos K, et al. . Gut-origin sepsis in the critically ill patient: pathophysiology and treatment. Infection 2018;46:751&#x2013;60. 10.1007/s15010-018-1178-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-018-1178-5</ArticleId><ArticleId IdType="pubmed">30003491</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin-Gallausiaux C, Larraufie P, Jarry A, et al. . Butyrate produced by commensal bacteria down-regulates indolamine 2,3-dioxygenase 1 (IDO-1) expression via a dual mechanism in human intestinal epithelial cells. Front Immunol 2018;9:2838. 10.3389/fimmu.2018.02838</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02838</ArticleId><ArticleId IdType="pmc">PMC6297836</ArticleId><ArticleId IdType="pubmed">30619249</ArticleId></ArticleIdList></Reference><Reference><Citation>Manfredo Vieira S, Hiltensperger M, Kumar V, et al. . Translocation of a gut pathobiont drives autoimmunity in mice and humans. Science 2018;359:1156&#x2013;61. 10.1126/science.aar7201</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aar7201</ArticleId><ArticleId IdType="pmc">PMC5959731</ArticleId><ArticleId IdType="pubmed">29590047</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Meng X, Chen B, et al. . Gut microbiota in lupus: a butterfly effect? Curr Rheumatol Rep 2021;23:27. 10.1007/s11926-021-00986-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-021-00986-z</ArticleId><ArticleId IdType="pubmed">33864162</ArticleId></ArticleIdList></Reference><Reference><Citation>Colucci R, Moretti S. Implication of human bacterial gut microbiota on immune-mediated and autoimmune dermatological diseases and their comorbidities: a narrative review. Dermatol Ther (Heidelb) 2021;11:363&#x2013;84. 10.1007/s13555-021-00485-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13555-021-00485-0</ArticleId><ArticleId IdType="pmc">PMC8018919</ArticleId><ArticleId IdType="pubmed">33507493</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Liu Q, Yu Y, et al. . Early and short-term interventions in the gut microbiota affects lupus severity, progression, and treatment in MRL/lpr mice. Front Microbiol 2020;11:628. 10.3389/fmicb.2020.00628</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2020.00628</ArticleId><ArticleId IdType="pmc">PMC7171286</ArticleId><ArticleId IdType="pubmed">32346376</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn A, Bonsmann G, Anders H-J, et al. . The diagnosis and treatment of systemic lupus erythematosus. Dtsch Arztebl Int 2015;112:423&#x2013;32. 10.3238/arztebl.2015.0423</Citation><ArticleIdList><ArticleId IdType="doi">10.3238/arztebl.2015.0423</ArticleId><ArticleId IdType="pmc">PMC4558874</ArticleId><ArticleId IdType="pubmed">26179016</ArticleId></ArticleIdList></Reference><Reference><Citation>Tunnicliffe DJ, Singh-Grewal D, Kim S, et al. . Diagnosis, monitoring, and treatment of systemic lupus erythematosus: a systematic review of clinical practice guidelines. Arthritis Care Res (Hoboken) 2015;67:1440&#x2013;52. 10.1002/acr.22591</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.22591</ArticleId><ArticleId IdType="pubmed">25778500</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy G, Isenberg DA. New therapies for systemic lupus erythematosus-past imperfect, future tense. Nat Rev Rheumatol 2019;15:403&#x2013;12. 10.1038/s41584-019-0235-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-019-0235-5</ArticleId><ArticleId IdType="pubmed">31165780</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarra SV, Guzm&#xe1;n RM, Gallacher AE, et al. . Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. The Lancet 2011;377:721&#x2013;31. 10.1016/S0140-6736(10)61354-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61354-2</ArticleId><ArticleId IdType="pubmed">21296403</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F, Bae S-C, Bass D, et al. . A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis 2018;77:355&#x2013;63. 10.1136/annrheumdis-2017-211631</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-211631</ArticleId><ArticleId IdType="pmc">PMC5867402</ArticleId><ArticleId IdType="pubmed">29295825</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramanujam M, Wang X, Huang W, et al. . Mechanism of action of transmembrane activator and calcium modulator ligand interactor-ig in murine systemic lupus erythematosus. J Immunol 2004;173:3524&#x2013;34. 10.4049/jimmunol.173.5.3524</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.173.5.3524</ArticleId><ArticleId IdType="pubmed">15322217</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Qing P, Yang H, et al. . Gut microbiome and metabolites in systemic lupus erythematosus: link, mechanisms and intervention. Front Immunol 2021;12:686501. 10.3389/fimmu.2021.686501</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.686501</ArticleId><ArticleId IdType="pmc">PMC8319742</ArticleId><ArticleId IdType="pubmed">34335588</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BM, Gaudreau M-C, Al-Gadban MM, et al. . Impact of dietary deviation on disease progression and gut microbiome composition in lupus-prone Snf1 mice. Clin Exp Immunol 2015;181:323&#x2013;37. 10.1111/cei.12609</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.12609</ArticleId><ArticleId IdType="pmc">PMC4516448</ArticleId><ArticleId IdType="pubmed">25703185</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieira SM, Pagovich OE, Kriegel MA. Diet, microbiota and autoimmune diseases. Lupus 2014;23:518&#x2013;26. 10.1177/0961203313501401</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203313501401</ArticleId><ArticleId IdType="pmc">PMC4009622</ArticleId><ArticleId IdType="pubmed">24763536</ArticleId></ArticleIdList></Reference><Reference><Citation>Reifen R, Amital H, Blank M, et al. . Linseed oil suppresses the anti-beta-2-glycoprotein-I in experimental antiphospholipid syndrome. J Autoimmun 2000;15:381&#x2013;5. 10.1006/jaut.2000.0439</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jaut.2000.0439</ArticleId><ArticleId IdType="pubmed">11040078</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuen HK, Cunningham MA. Optimal management of fatigue in patients with systemic lupus erythematosus: a systematic review. Ther Clin Risk Manag 2014;10:775&#x2013;86. 10.2147/TCRM.S56063</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/TCRM.S56063</ArticleId><ArticleId IdType="pmc">PMC4199565</ArticleId><ArticleId IdType="pubmed">25328393</ArticleId></ArticleIdList></Reference><Reference><Citation>Klack K, Bonfa E, Neto EFB. Diet and nutritional aspects in systemic lupus erythematosus. Rev Bras Reumatol 2012;52:395&#x2013;408. 10.1590/S0482-50042012000300009</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S0482-50042012000300009</ArticleId><ArticleId IdType="pubmed">22641593</ArticleId></ArticleIdList></Reference><Reference><Citation>Bello KJ, Fang H, Fazeli P, et al. . Omega-3 in SLE: a double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus. Rheumatol Int 2013;33:2789&#x2013;96. 10.1007/s00296-013-2811-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-013-2811-3</ArticleId><ArticleId IdType="pmc">PMC3805738</ArticleId><ArticleId IdType="pubmed">23817872</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriens C, Hynan LS, Lerman RH, et al. . Placebo-controlled randomized clinical trial of fish oil&#x2019;s impact on fatigue, quality of life, and disease activity in systemic lupus erythematosus. Nutr J 2015;14:82. 10.1186/s12937-015-0068-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12937-015-0068-2</ArticleId><ArticleId IdType="pmc">PMC4538741</ArticleId><ArticleId IdType="pubmed">26283629</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharya A, Sun D, Rahman M, et al. . Different ratios of eicosapentaenoic and docosahexaenoic omega-3 fatty acids in commercial fish oils differentially alter pro-inflammatory cytokines in peritoneal macrophages from C57BL/6 female mice. J Nutr Biochem 2007;18:23&#x2013;30. 10.1016/j.jnutbio.2006.02.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jnutbio.2006.02.005</ArticleId><ArticleId IdType="pubmed">16563716</ArticleId></ArticleIdList></Reference><Reference><Citation>Duffy EM, Meenagh GK, McMillan SA, et al. . The clinical effect of dietary supplementation with omega-3 fish oils and/or copper in systemic lupus erythematosus. J Rheumatol 2004;31:1551&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15290734</ArticleId></ArticleIdList></Reference><Reference><Citation>Constantin M-M, Nita IE, Olteanu R, et al. . Significance and impact of dietary factors on systemic lupus erythematosus pathogenesis. Exp Ther Med 2019;17:1085&#x2013;90. 10.3892/etm.2018.6986</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2018.6986</ArticleId><ArticleId IdType="pmc">PMC6327661</ArticleId><ArticleId IdType="pubmed">30679978</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora JR, Iwata M, von Andrian UH. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol 2008;8:685&#x2013;98. 10.1038/nri2378</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2378</ArticleId><ArticleId IdType="pmc">PMC2906676</ArticleId><ArticleId IdType="pubmed">19172691</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu Q, Zhang H, Luo XM. SLE: another autoimmune disorder influenced by microbes and diet? Front Immunol 2015;6:608. 10.3389/fimmu.2015.00608</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2015.00608</ArticleId><ArticleId IdType="pmc">PMC4663251</ArticleId><ArticleId IdType="pubmed">26648937</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinoshita K, Kishimoto K, Shimazu H, et al. . Successful treatment with retinoids in patients with lupus nephritis. Am J Kidney Dis 2010;55:344&#x2013;7. 10.1053/j.ajkd.2009.06.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2009.06.012</ArticleId><ArticleId IdType="pubmed">19628316</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo X, Yang X, Li Q, et al. . The microbiota in systemic lupus erythematosus: an update on the potential function of probiotics. Front Pharmacol 2021;12:759095. 10.3389/fphar.2021.759095</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.759095</ArticleId><ArticleId IdType="pmc">PMC8650621</ArticleId><ArticleId IdType="pubmed">34887760</ArticleId></ArticleIdList></Reference><Reference><Citation>Esmaeili S-A, Mahmoudi M, Momtazi AA, et al. . Tolerogenic probiotics: potential immunoregulators in systemic lupus erythematosus. J Cell Physiol 2017;232:1994&#x2013;2007. 10.1002/jcp.25748</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.25748</ArticleId><ArticleId IdType="pubmed">27996081</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffer C, Lalanne AI, Cassard L, et al. . A strain of Lactobacillus casei inhibits the effector phase of immune inflammation. J Immunol 2011;187:2646&#x2013;55. 10.4049/jimmunol.1002415</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1002415</ArticleId><ArticleId IdType="pubmed">21810608</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlasova AN, Kandasamy S, Chattha KS, et al. . Comparison of probiotic lactobacilli and bifidobacteria effects, immune responses and rotavirus vaccines and infection in different host species. Vet Immunol Immunopathol 2016;172:72&#x2013;84. 10.1016/j.vetimm.2016.01.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vetimm.2016.01.003</ArticleId><ArticleId IdType="pmc">PMC4818210</ArticleId><ArticleId IdType="pubmed">26809484</ArticleId></ArticleIdList></Reference><Reference><Citation>de Oliveira GLV, Leite AZ, Higuchi BS, et al. . Intestinal dysbiosis and probiotic applications in autoimmune diseases. Immunology 2017;152:1&#x2013;12. 10.1111/imm.12765</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.12765</ArticleId><ArticleId IdType="pmc">PMC5543467</ArticleId><ArticleId IdType="pubmed">28556916</ArticleId></ArticleIdList></Reference><Reference><Citation>Mike A, Nagaoka N, Tagami Y, et al. . Prevention of B220+ T cell expansion and prolongation of lifespan induced by Lactobacillus casei in MRL/lpr mice. Clin Exp Immunol 1999;117:368&#x2013;75. 10.1046/j.1365-2249.1999.00951.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2249.1999.00951.x</ArticleId><ArticleId IdType="pmc">PMC1905353</ArticleId><ArticleId IdType="pubmed">10444272</ArticleId></ArticleIdList></Reference><Reference><Citation>Mardani F, Mahmoudi M, Esmaeili S-A, et al. . In vivo study: th1-th17 reduction in pristane-induced systemic lupus erythematosus mice after treatment with tolerogenic Lactobacillus probiotics. J Cell Physiol 2018;234:642&#x2013;9. 10.1002/jcp.26819</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.26819</ArticleId><ArticleId IdType="pubmed">30078223</ArticleId></ArticleIdList></Reference><Reference><Citation>Konturek PC, Koziel J, Dieterich W, et al. . Successful therapy of clostridium difficile infection with fecal microbiota transplantation. J Physiol Pharmacol Off J Pol Physiol Soc 2016;67:859&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">28195066</ArticleId></ArticleIdList></Reference><Reference><Citation>Smits LP, Bouter KEC, de Vos WM, et al. . Therapeutic potential of fecal microbiota transplantation. Gastroenterology 2013;145:946&#x2013;53. 10.1053/j.gastro.2013.08.058</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2013.08.058</ArticleId><ArticleId IdType="pubmed">24018052</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Zhu Z, Lin X, et al. . Gut microbiota mediated the therapeutic efficacies and the side effects of prednisone in the treatment of MRL/lpr mice. Arthritis Res Ther 2021;23:240. 10.1186/s13075-021-02620-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-021-02620-w</ArticleId><ArticleId IdType="pmc">PMC8439074</ArticleId><ArticleId IdType="pubmed">34521450</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamudio Tiburcio &#xc1;. Improvement in a patient with active systemic lupus erythematosous treated with transplant of intestinal microbiota. GMR 2019;3:3. 10.31031/GMR.2019.03.000551</Citation><ArticleIdList><ArticleId IdType="doi">10.31031/GMR.2019.03.000551</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Yi P, Zhu M, et al. . Safety and efficacy of fecal microbiota transplantation for treatment of systemic lupus erythematosus: an explorer trial. J Autoimmun 2022;130:102844. 10.1016/j.jaut.2022.102844</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2022.102844</ArticleId><ArticleId IdType="pubmed">35690527</ArticleId></ArticleIdList></Reference><Reference><Citation>He H, Xu H, Xu J, et al. . Sodium butyrate ameliorates gut microbiota dysbiosis in lupus-like mice. Front Nutr 2020;7:604283. 10.3389/fnut.2020.604283</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnut.2020.604283</ArticleId><ArticleId IdType="pmc">PMC7688247</ArticleId><ArticleId IdType="pubmed">33262998</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, Chan T, Hong X, et al. . Microbiome and metabolome analyses reveal the disruption of lipid metabolism in systemic lupus erythematosus. Front Immunol 2020;11:1703. 10.3389/fimmu.2020.01703</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01703</ArticleId><ArticleId IdType="pmc">PMC7411142</ArticleId><ArticleId IdType="pubmed">32849599</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen M, Liu T, Zhao M, et al. . Correlation analysis between gut microbiota and metabolites in children with systemic lupus erythematosus. J Immunol Res 2021;2021:5579608. 10.1155/2021/5579608</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/5579608</ArticleId><ArticleId IdType="pmc">PMC8325587</ArticleId><ArticleId IdType="pubmed">34341764</ArticleId></ArticleIdList></Reference><Reference><Citation>Toumi E, Goutorbe B, Plauzolles A, et al. . Gut microbiota in systemic lupus erythematosus patients and lupus mouse model: a cross species comparative analysis for biomarker discovery. Front Immunol 2022;13:943241. 10.3389/fimmu.2022.943241</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.943241</ArticleId><ArticleId IdType="pmc">PMC9378784</ArticleId><ArticleId IdType="pubmed">35983031</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>